![Toshiyuki Mori](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Toshiyuki Mori is an Independent Outside Director at J-Pharma Co., Ltd. since 2020 and an Outside Director at EditForce, Inc. since 2019.
Former roles include Independent Outside Director at Ribomic, Inc.
| Sociétés | Poste | Début |
|---|---|---|
| J-PHARMA CO., LTD. | Directeur/Membre du Conseil | 01/06/2020 |
Editforce, Inc.
 Editforce, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in research, development and production of medicinal drugs | Directeur/Membre du Conseil | 01/03/2019 |
| Sociétés | Poste | Fin |
|---|---|---|
| RIBOMIC INC. | Directeur/Membre du Conseil | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
| Entreprise privées | 3 |
|---|---|
Ribomic, Inc.
 Ribomic, Inc. Pharmaceuticals: MajorHealth Technology Manufactures aptamer drug | Health Technology |
J-Pharma Co., Ltd.
 J-Pharma Co., Ltd. BiotechnologyHealth Technology Engages in research and development and drug discovery services | Health Technology |
Editforce, Inc.
Editforce, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in research, development and production of medicinal drugs | Commercial Services |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
